Equities research analysts at Barclays PLC assumed coverage on shares of Vitamin Shoppe Inc. (NYSE:VSI) in a report released on Thursday. The brokerage set an “equal weight” rating on the stock.

A number of other analysts have also recently commented on the stock. Jefferies Group reissued a “hold” rating on shares of Vitamin Shoppe in a research note on Thursday, August 4th. Wedbush reissued an “outperform” rating and set a $39.00 target price on shares of Vitamin Shoppe in a research note on Wednesday, August 3rd. Finally, Zacks Investment Research cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $32.82.

Shares of Vitamin Shoppe (NYSE:VSI) traded up 2.72% during mid-day trading on Thursday, reaching $27.55. 185,513 shares of the company’s stock traded hands. The company’s 50-day moving average price is $27.17 and its 200-day moving average price is $29.34. The stock has a market capitalization of $649.74 million, a PE ratio of 16.14 and a beta of 0.67. Vitamin Shoppe has a 12-month low of $26.02 and a 12-month high of $34.41.

Vitamin Shoppe (NYSE:VSI) last released its earnings results on Wednesday, August 3rd. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $332.70 million for the quarter, compared to analysts’ expectations of $331.58 million. Vitamin Shoppe had a return on equity of 11.53% and a net margin of 3.56%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.57 EPS. Analysts anticipate that Vitamin Shoppe will post $2.17 earnings per share for the current year.

Several institutional investors have recently modified their holdings of VSI. Envestnet Asset Management Inc. raised its position in shares of Vitamin Shoppe by 10.0% in the first quarter. Envestnet Asset Management Inc. now owns 4,068 shares of the company’s stock valued at $126,000 after buying an additional 371 shares in the last quarter. Acrospire Investment Management LLC bought a new position in shares of Vitamin Shoppe during the second quarter valued at approximately $135,000. Mason Street Advisors LLC bought a new position in shares of Vitamin Shoppe during the second quarter valued at approximately $145,000. BlackRock Inc. raised its position in shares of Vitamin Shoppe by 241.2% in the second quarter. BlackRock Inc. now owns 6,541 shares of the company’s stock valued at $200,000 after buying an additional 4,624 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Vitamin Shoppe by 932.1% in the second quarter. Daiwa Securities Group Inc. now owns 7,400 shares of the company’s stock valued at $226,000 after buying an additional 6,683 shares in the last quarter.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, which includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats; direct, which sells its products directly to consumers through the Internet, primarily at www.vitaminshoppe.com, and manufacturing, which provides custom manufacturing and private labeling of vitamin, mineral and supplement (VMS) products.

5 Day Chart for NYSE:VSI

Receive News & Ratings for Vitamin Shoppe Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc. and related companies with MarketBeat.com's FREE daily email newsletter.